Novavax, Inc. (NVAX)
NASDAQ: NVAX · Real-Time Price · USD
7.95
+0.06 (0.76%)
At close: Aug 11, 2026, 4:00 PM EDT
7.92
-0.03 (-0.38%)
After-hours: Aug 11, 2026, 7:56 PM EDT

Novavax Revenue

Novavax had revenue of $56.70M in the quarter ending June 30, 2026, a decrease of -76.30%. This brings the company's revenue in the last twelve months to $413.80M, down -61.64% year-over-year. In the year 2025, Novavax had annual revenue of $1.12B with 64.69% growth.

Revenue (ttm)
$413.80M
Revenue Growth
-61.64%
P/S Ratio
3.17
Revenue / Employee
$552,465
Employees
749
Market Cap
1.31B

Revenue Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 20251.12B441.32M64.69%
Dec 31, 2024682.16M-301.54M-30.65%
Dec 31, 2023983.71M-998.17M-50.36%
Dec 31, 20221.98B835.58M72.89%
Dec 31, 20211.15B670.69M141.02%
Dec 31, 2020475.60M456.94M2,448.48%
Dec 31, 201918.66M-15.63M-45.57%
Dec 31, 201834.29M3.11M9.98%
Dec 31, 201731.18M15.82M103.06%
Dec 31, 201615.35M-20.90M-57.65%
Dec 31, 201536.25M5.59M18.24%
Dec 31, 201430.66M9.74M46.59%
Dec 31, 201320.92M-1.16M-5.26%
Dec 31, 201222.08M7.39M50.30%
Dec 31, 201114.69M14.35M4,182.22%
Dec 31, 2010343.00K18.00K5.54%
Dec 31, 2009325.00K-739.00K-69.45%
Dec 31, 20081.06M-449.00K-29.68%
Dec 31, 20071.51M-225.00K-12.95%
Dec 31, 20061.74M-3.61M-67.47%
Dec 31, 20055.34M--

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Related Stocks

Company NameRevenue
MannKind393.63M
MeiraGTx Holdings79.76M
Immatics43.00M
Monte Rosa Therapeutics28.73M
Aktis Oncology8.28M
Inhibrx Biosciences1.30M
Revenue Rankings